Medicine and Dentistry
Von Willebrand Factor
100%
Blood Flow
83%
Skeletal Muscle
77%
Contrast-Enhanced Ultrasound
61%
Thrombocyte Adhesion
58%
Platelet
54%
Sickle-Cell Disease
51%
Scintigraphy
37%
Von Willebrand Factor Cleaving Proteinase
37%
Molecular Imaging
37%
Microangiopathy
33%
Hypercholesterolemia
33%
Ponatinib
33%
Cohort Analysis
33%
Apheresis
33%
Cardiovascular Toxicity
33%
Hydroxyurea
33%
Hemangioendothelioma
33%
Patient with Sickle Cell Disease
33%
Coronary Microvascular Dysfunction
33%
Genetic Transfection
33%
Tyrosine-Kinase Inhibitor
33%
Radiation Therapy
33%
Drug Megadose
33%
Lipoprotein Apheresis
33%
Limb
33%
Complementary DNA
33%
Atherogenesis
33%
Vincristine
26%
Rapamycin
26%
Tufted Angioma
26%
Hindlimb
24%
Anemia
21%
Myocardial Infarction
20%
Treatment Response
20%
Erythrocyte Deformability
20%
Heart Muscle Perfusion
16%
Muscle Perfusion
15%
Contralateral
14%
Gene Targeting
13%
Transgene
13%
Vascular Tissue Neoplasm
13%
Globin
13%
Heart Work
13%
Thrombocyte Aggregation
12%
Infarction
12%
Pathophysiology
10%
Clinical Trial
10%
Low Density Lipoprotein Cholesterol
9%
Ex Vivo
9%
Keyphrases
Thromboinflammation
33%
Von Willebrand Factor
33%
Ultrasound Cavitation
33%
ATP Signaling
33%
Tyrosine Kinase Inhibitor
33%
Atherogenesis
33%
Thrombotic Complications
33%
Hydroxycarbamide
33%
Platelets
33%
Tyrosine Kinase
25%
Myocardial Infarction
19%
Adverse Event Rates
16%
High-dose Irradiation
13%
Angiopathy
12%
Atherosclerotic Plaque
11%
Atherothrombotic Event
11%
Platelet Integrin
11%
Platelet Glycoproteins
11%
Platelet Activation
11%
Platelet Adhesion
11%
Platelet-derived Growth factor-BB (PDGF-BB)
11%
Mural Cells
11%
Platelet Aggregation
11%
Therapeutic Target
11%
Supersaturation
10%
Platelet-derived Growth Factor Receptor (PDGFR)
8%
Vascular Events
8%
Drug Resistance
8%
Neovascularization
8%
Vascular Endothelial Growth Factor Receptor (VEGFR)
8%
Metastasis
8%
Critical Limb Ischemia
8%
Immune Surveillance
8%
Hematological Malignancies
8%
Breakpoint Cluster Region
8%
Clinical Experience
8%
Targeting Strategies
8%
Tumor Growth
8%
Abnormal Expression
8%
Mitigation Strategies
8%
Solid Malignancies
8%
Treatment Durability
6%
Proximal Area
6%
Dynamic Wedges
6%
Ectonucleotidases
6%
ATP Degradation
6%
Background Augmentation
6%
Alarmins
6%
Vaso-occlusive Events
5%
High Shear Stress
5%
Pharmacology, Toxicology and Pharmaceutical Science
Von Willebrand Factor
66%
Heart Infarction
37%
Cohort Study
33%
Von Willebrand Factor Cleaving Proteinase
33%
Atherogenesis
33%
Protein Tyrosine Kinase Inhibitor
33%
Complementary DNA
33%
Hemangioendothelioma
33%
Angioma
26%
Rapamycin
26%
Vincristine
26%
Protein Tyrosine Kinase
25%
Mouse
16%
Adverse Event
16%
Integrin
16%
Glycoprotein
16%
Wild Type Mouse
16%
Gene Delivery
13%
Vascular Tumor
13%
Disease
13%
Infarction
12%
Tumor Growth
8%
Drug Resistance
8%
Vasculotropin Receptor
8%
Platelet Derived Growth Factor Receptor
8%
Neovascularization (Pathology)
8%
Hematologic Malignancy
8%
Malignant Neoplasm
8%
Critical Limb Ischemia
8%
Ischemia
8%
Epileptic Absence
6%
Clinical Trial
6%
Mortality Rate
6%
Alarmin
5%
